

2021 Factor Investing Mid-Year Review Part I: Importance of Factors in the Portfolio Construction Process

Featuring:

Raina Oberoi, Managing Director, MSCI Research

Andrew Ang, Head of Factor Investing Strategies, BlackRock

Raina Oberoi:

Thanks Jenna, for having me. And Andrew as always, it's a pleasure sharing the stage with you. What a wild year this has been, touching literally every part of our lives. Now, while markets were anticipating a vaccine announcement late last year, the actual announcement November 9th, that we now actually have vaccines that are more than 90% effective in preventing COVID-19, has been a game changer, and a key trigger for some big shifts across markets and factors in particular.

Now, while equity markets demonstrated resilience during a period of really high economic uncertainty, what we saw in Q4 of 2020, given the vaccine announcement and Joe Biden winning the US presidential election, was the fact that rotation really intensified. Momentum, which already has stretched valuations at the end of Q3 pullback, and we saw value stock, which has underperformed for a majority of the year, add gains in literally every region in a quite dramatic rotation. We saw small cap stocks significantly outperform their larger cap counterparts, reversing yet another trend. And investors favored higher beta stocks over lower beta stocks. We've seen some of these same trends persist as we've entered 2021.

Now, I think I won't do justice if I didn't spend some time on discussing the resurgence of value as economies started opening up. In fact, I believe in the last State of the Union in fall of 2020, Andrew had discussed the potential of a comeback in value, as these stocks do tend to outperform during the recovery. And what we saw is actually value did find its trigger in the vaccine announcement and the reopening of the economies.

Now, in the chart here, you actually see a clear out-performance of value starting on November 9th, 2020, reversing a really long trend. And the reason value is such a key topic to discuss is that after 15 years of challenging performance, investors were actually beginning to question whether value is still a valid investment strategy. Many proclaim that value is dead, and that there is no longer a premium associated with investing in such stocks. But

what we have seen is that the reopening of the global economy following the rollout of the COVID-19 vaccinations has once again triggered and reignited interest in value strategies.

Now, as we have gone further into 2021, we have seen some trends reverse. Momentum, for example, which had plummeted since the vaccine announcement, showed better performance in the second quarter of this year. Now, one would wonder, well, what changed? And actually, there was no new trigger this time, but just that momentum did what it typically does. Momentum by definition, rotates to the securities with recent outperformance, regardless of other factor, sector, or country exposures.

Now, if you take, for example, the MSCI momentum indexes as a proxy, we saw these indexes rotate into securities with higher value and lower growth characteristics. And that's because value stocks outperformed in the last six months, and growth stock showed weaker performance in the same time period.

So as a result of these changes in relative factor performance over the last six months, securities of higher value exposure started to exhibit higher momentum characteristics. And we now see an increased value in momentum correlation. Simultaneously, we saw poor performing growth, low volatility and quality stocks decrease the momentum characteristics.

So, what is important to note is that momentum has reshuffled between factors in the past as well. So, while it may seem right now, that momentum is on the hunt for securities with higher value characteristics, that's only because value is doing well and it's in favor. Now, if that changes, momentum will target other characteristics.

So, I think it's important to understand not only the nuances of a single factor like momentum, but also how does it interact with other factors. And this has been a really good reminder for investors as well, to really take a holistic view on factors, and understand their dynamic between each other.

Finally, I would say, another interesting theme that we saw in the US in particular was the rise of market concentration. That is, a handful of mega cap companies increased their market share in US equity markets, exposing some investors to concentration risk. We also saw US equity markets experiencing increased volatility over the last few years.

So once again, a natural question investors had on their mind is, well, does this hamper investors' ability to capture style-related investment characteristics, or what we call factors, in an effective fashion? You also had some investors wonder that have stock-specific risks now, dominated factor portfolios instead, because now the market seems more concentrated, and it's dominated by just a few stocks. And what we found in our analysis is that actually MSCI's factor indexes and related factor portfolios remain quite robust, and factors still played a key role in explaining risks.

Finally, I would say to conclude, what we saw in these unprecedented months was that understanding and managing portfolio investment characteristics, or what we call factors, remained absolutely critical to the investment process. Thank you. And back to you, Jenna.

Andrew Ang:

Thank you very much. And Raina, it's always a pleasure to talk with you. And I think really, I'm looking forward to the second half of 2021, going back to some semblance of normalcy. And we can see that. We can see increased traffic on the streets, people going back to work, people now being able to meet their friends and help their family. And this is all great. And it's also seen us with what Raina called this dramatic reversal from growth into value. And that's the topic that I want to talk about.

This has been tremendous, this dramatic reversal. We will look at from November 9th, and Raina mentioned that date. This is Pfizer day. It's when we got the first news that there was an effective vaccine against the coronavirus. The difference between value and growth, say in Russell Industries, is about 20%. We've seen year-to-date, our performance that's been terrific as well. If we look at the flows coming into value strategies, we can look at the flow into VLUE, or US value, and that's been around \$5 billion. So, this trend has been recognized by investors too.

I want to make three comments about this value resurgence. First, we have a lot further to run. Second, there is a way to actually hop on at the very beginning of a new value trend, and that's international value. And I'll elaborate on that. And the third one is that if we're looking for a compliment to this dramatic reversal of value, then I advocate that quality can be considered by investors.

So, let's turn to each of these three. There is still a long way to run with value. If we look at this slide, our value underperformance since 2017 to the end of 2020, with the comeback really from that Pfizer day of the beginning of November 2017 to 2020 is the worst value drawdown in approximately a hundred years of data, using this data from Fama and French. It is the longest duration of the drawdown as well. So, we hit from 2017 to the low of 2020, a drawdown of about minus 60%. Now, we've clawed our way back for some of that, but we still have a long way to go.

From 2017 to 2020, we've had a really late, prolonged slowdown at the late stage of an economic cycle. And then in 2020, we got hit with the coronavirus, exacerbating this. And the coronavirus all sent us into lockdown, where we had growth technology companies doing very well. And that penalizes the value companies who are usually long physical capital. But since that reopening, we've seen that dramatic reversal into value. The fact that it's been just so bad over so many years, means that we have a long way to go.

Okay, the second one is, if we look at international value, 2020 was the second worst year for international value in approximately a century of data. Now, international value is interesting because we've seen this reopening of the economy in the United States. There are some countries like the US, that have very high vaccination rates, countries like Israel and Canada. But most of the rest of the world, including most of Europe and Asia, lag behind the vaccination rates of the US. Asia is interesting because they were really good at handling, by and large, the lockdown in 2020, and containing the coronavirus. But they've been slower to adopt vaccinations for their populations.

So, as we go back to that reopening, there will be further reopening for these other international markets, which the US has really led. So, we can still look at going on this resurgence for value, and we can play that at the beginning with international value strategies.

Last, I want to leave a compliment. Value and quality are negatively correlated at around minus 20%. And that minus correlation is really absolutely terrific for diversification in our portfolios. Why? Well, if we look at value, value is all about buying cheap. Those cheap companies are typically long physical assets, and that's been rewarded as the economy reopens.

If we look at quality, quality is really a statement about the numerator in a dividend discount model. We want things like high productivity or ROE. We'd like to look at how to service that debt or low leverage, and we want lower volatility of earnings. Value buys cheap, so it's mostly a discount rate, what enters the denominator of that pricing formula. So quality is all about the numerator, and value is all about the denominator. Not surprisingly, value and quality are really good compliments. Quality gives us that resistance, that robustness just in case we see further variants coming out. Or we might enter again, hopefully a very transitory period of lockdowns.

But we are on track. The economy is here, it's reopening. And me, myself, I think, like you, were looking really forward to going back to some sense of normalcy. Thank you, Jenna.

About MSCI

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com.

This document and all of the information contained in it, including without limitation all text, data, graphs, charts (collectively, the "Information") is the property of MSCI Inc. or its subsidiaries (collectively, "MSCI"), or MSCI's licensors, direct or indirect suppliers or any third party involved in making or compiling any Information (collectively, with MSCI, the "Information Providers") and is provided for informational purposes only. The Information may not be modified, reverse-engineered, reproduced or disseminated in whole or in part without prior written permission from MSCI.

The Information may not be used to create derivative works or to verify or correct other data or information. For example (but without limitation), the Information may not be used to create indexes, databases, risk models, analytics, software, or in connection with the issuing, offering, sponsoring, managing or marketing of any securities, portfolios, financial products or other investment vehicles utilizing or based on, linked to, tracking or otherwise derived from the Information or any other MSCI data, information, products or services.

The user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF THE INFORMATION PROVIDERS MAKES ANY EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE INFORMATION (OR THE RESULTS TO BE OBTAINED BY THE USE THEREOF), AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EACH INFORMATION PROVIDER EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES (INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF ORIGINALITY, ACCURACY, TIMELINESS, NON-INFRINGEMENT, COMPLETENESS, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO ANY OF THE INFORMATION.

Without limiting any of the foregoing and to the maximum extent permitted by applicable law, in no event shall any Information Provider have any liability regarding any of the Information for any direct, indirect, special, punitive, consequential (including lost profits) or any other damages even if notified of the possibility of such damages. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited, including without limitation (as applicable), any liability for death or personal injury to the extent that such injury results from the negligence or willful default of itself, its servants, agents or sub-contractors.

Information containing any historical information, data or analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. Past performance does not guarantee future results.

The Information should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. All Information is impersonal and not tailored to the needs of any person, entity or group of persons.

None of the Information constitutes an offer to sell (or a solicitation of an offer to buy), any security, financial product or other investment vehicle or any trading strategy.

It is not possible to invest directly in an index. Exposure to an asset class or trading strategy or other category represented by an index is only available through third party investable instruments (if any) based on that index. MSCI does not issue, sponsor, endorse, market, offer, review or otherwise express any opinion regarding any fund, ETF, derivative or other security, investment, financial product or trading strategy that is based on, linked to or seeks to provide an investment return related to the performance of any MSCI index (collectively, "Index Linked Investments"). MSCI makes no assurance that any Index Linked Investments will accurately track index performance or provide positive investment returns. MSCI Inc. is not an investment adviser or fiduciary and MSCI makes no representation regarding the advisability of investing in any Index Linked Investments.

Index returns do not represent the results of actual trading of investible assets/securities. MSCI maintains and calculates indexes, but does not manage actual assets. Index returns do not reflect payment of any sales charges or fees an investor may pay to purchase the securities underlying the index or Index Linked Investments. The imposition of these fees and charges would cause the performance of an Index Linked Investment to be different than the MSCI index performance.

The Information may contain back tested data. Back-tested performance is not actual performance, but is hypothetical. There are frequently material differences between back tested performance results and actual results subsequently achieved by any investment strategy.

Constituents of MSCI equity indexes are listed companies, which are included in or excluded from the indexes according to the application of the relevant index methodologies. Accordingly, constituents in MSCI equity indexes may include MSCI Inc., clients of MSCI or suppliers to MSCI. Inclusion of a security within an MSCI index is not a recommendation by MSCI to buy, sell, or hold such security, nor is it considered to be investment advice.

Data and information produced by various affiliates of MSCI Inc., including MSCI ESG Research LLC and Barra LLC, may be used in calculating certain MSCI indexes. More information can be found in the relevant index methodologies on www.msci.com.

MSCI receives compensation in connection with licensing its indexes to third parties. MSCI Inc.'s revenue includes fees based on assets in Index Linked Investments. Information can be found in MSCI Inc.'s company filings on the Investor Relations section of www.msci.com.

MSCI ESG Research LLC is a Registered Investment Adviser under the Investment Advisers Act of 1940 and a subsidiary of MSCI Inc. Except with respect to any applicable products or services from MSCI ESG Research, neither MSCI nor any of its products or services recommends, endorses, approves or otherwise expresses any opinion regarding any issuer, securities, financial products or instruments or trading strategies and MSCI's products or services are not intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Issuers mentioned or included in any MSCI ESG Research materials may include MSCI Inc., clients of MSCI or suppliers to MSCI, and may also purchase research or other products or services from MSCI ESG Research. MSCI ESG Research materials, including materials utilized in any MSCI ESG Indexes or other products, have not been submitted to, nor received approval from, the United States Securities and Exchange Commission or any other regulatory body.

Any use of or access to products, services or information of MSCI requires a license from MSCI. MSCI, Barra, RiskMetrics, IPD and other MSCI brands and product names are the trademarks, service marks, or registered trademarks of MSCI or its subsidiaries in the United States and other jurisdictions. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's. "Global Industry Classification Standard (GICS)" is a service mark of MSCI and Standard & Poor's.

MIFID2/MIFIR notice: MSCI ESG Research LLC does not distribute or act as an intermediary for financial instruments or structured deposits, nor does it deal on its own account, provide execution services for others or manage client accounts. No MSCI ESG Research product or service supports, promotes or is intended to support or promote any such activity. MSCI ESG Research is an independent provider of ESG data, reports and ratings based on published methodologies and available to clients on a subscription basis. We do not provide custom or one-off ratings or recommendations of securities or other financial instruments upon request.

Privacy notice: For information about how MSCI ESG Research LLC collects and uses personal data concerning officers and directors, please refer to our Privacy Notice at <https://www.msci.com/privacy-pledge>.